TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the Company will participate in the upcoming Needham & Company Growth Conference. Relevant details include: Date:January 14, 2025Conference:Needham & Company 27th Annual Growth ConferencePresentation Time:8:45 a.m. ETFormatFireside ChatEvent URL:https://investors.cellebrite.com/events/event-deta ...

Thomas E. Hogan confirmed as interim CEOTYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced a series of Board updates to support the Company’s continued growth into 2025 and beyond. As previously detailed on November 6, 2024, Thomas E. Hogan has been appointed interim CEO to begin 2025 as part of a planned leadership transition. In conjunction wi ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cellebrite (Nasdaq: CLBT), a global leader in premier digital investigative solutions for the public and private sectors, and Relativity, a global legal technology company, announced today the general availability of the integration of Cellebrite’s mobile collection solutions, Endpoint Inspector and Endpoint Mobile Now, into the RelativityOne platform. The need for mobile collection in legal processes continues to grow and this ne ...

Core Insights - Investors in the Technology Services sector should consider Nu Holdings Ltd. (NU) and Cellebrite DI Ltd. (CLBT) for potential value opportunities [1] Valuation Metrics - Nu Holdings Ltd. has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Cellebrite DI Ltd. has a Zacks Rank of 3 (Hold) [3] - NU has a forward P/E ratio of 37.15, compared to CLBT's forward P/E of 44.66, suggesting NU is more attractively valued [5] - The PEG ratio for NU is 0.69, indicating better growth prospects relative to its valuation, while CLBT's PEG ratio is 1.95 [5] - NU's P/B ratio is 10.48, while CLBT's P/B ratio is 12.85, further supporting NU's superior valuation metrics [6] Investment Conclusion - NU has demonstrated stronger estimate revision activity and more favorable valuation metrics than CLBT, making it a more appealing option for value investors [7]

David focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. He is a long term investor of quality stocks and uses options for strategy. David told investors to buy in March 2009 at the bottom of the financial crisis. The S&P 500 increased 367% and the Nasdaq increased 685% from 2009 through 2019. He wants to help make people money by investing in high-quality growth stocks.Analyst’s Disclosure: I/we have no stock, option or similar derivative ...

I gave a buy rating to Cellebrite (NASDAQ: CLBT ) in August as I believed the upside is no longer attractive given that valuation has risen to 31x forward EBITDA. Looking at how the share price hasI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in buying quality companies at a discount to th ...

Cellebrite DI Ltd. (NASDAQ:CLBT) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Andrew Kramer - Investor Relations Yossi Carmil - CEO Dana Gerner - CFO Thomas Hogan - Executive Chairman Conference Call Participants Shaul Eyal - TD Cowen Michael Cikos - Needham Jeffrey Van Rhee - Craig-Hallum Brian Essex - JP Morgan Jonathan Ho - William Blair Tomer Zilberman - Bank of America Max Michaels - Lake Street Capital Operator Welcome to the Cellebrite Third Quarter 2024 Financial ...

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.27%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.10, delivering a surprise of 25%.Over the last four quarters, the company ...

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced a planned leadership transition following Yossi Carmil’s decision to step down from his current role as CEO and as a member of the Board of Directors by December 31, 2024. The Board has initiated a formal search for a new CEO, retaining an executive recruiting firm to advance this effort. Thomas ...

Exhibit 99.1 Cellebrite Announces Third-Quarter 2024 Results Third-quarter 2024 revenue of $106.9 million exceeds $100 million quarterly revenue milestone for the first time in Company history Third-quarter 2024 revenue increased 27% year-over-year primarily due to 27% growth in subscription revenue ARR of $370.8 million, up 26% year-over-year Third-quarter 2024 adjusted EBITDA of $31.3 million, 29.3% adjusted EBITDA margin Company increases 2024 outlook for revenue and adjusted EBITDA, and raises the low e ...